顶峰治疗

最新新闻

• 评级变动
  Bernstein Maintains Summit Therapeutics(SMMT.US) With Sell Rating, Raises Target Price to $9.8
  \u5e02\u573a\u8d44\u8baf · 2026/6/22
• 评级变动
  Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/6/1
• 评级变动
  Wells Fargo Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/8/27
• 评级变动
  Wolfe Research Initiates Summit Therapeutics(SMMT.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $16 to $40
  \u5e02\u573a\u8d44\u8baf · 2026/7/24
• 评级变动
  Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $38
  \u5e02\u573a\u8d44\u8baf · 2026/7/29
• 评级变动
  Jefferies Upgrades Summit Therapeutics(SMMT.US) to Buy Rating, Raises Target Price to $25
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  Citi Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/9/14
• 评级变动
  Clear Street Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $31
  \u5e02\u573a\u8d44\u8baf · 2026/9/3
• 评级变动
  TD Cowen Maintains Summit Therapeutics(SMMT.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/7/28
• 评级变动
  Guggenheim Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/6/1
• 评级变动
  A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $15 to $40
  \u5e02\u573a\u8d44\u8baf · 2026/7/25
• 评级变动
  Bernstein Maintains Summit Therapeutics(SMMT.US) With Sell Rating, Maintains Target Price $9.8
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $16 to $43
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• 评级变动
  UBS Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $33
  \u5e02\u573a\u8d44\u8baf · 2026/9/14
• Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Raises Target Price to $20
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Maintains Target Price $18
  \u5e02\u573a\u8d44\u8baf · 2026/9/21
• Goldman Sachs Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $41
  \u5e02\u573a\u8d44\u8baf · 2026/9/14

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。